Protocol summary
-
Study aim
-
Evaluation of the efficacy of prophylactic oral misoprostol in comparison with conventiinal treatment for reducing PPH (post-partum hemorrhage) in pre-clampsia
Evaluation of the efficacy of prophylactic rectal misoprostol in comparison with conventiinal treatment for reducing PPH (post-partum hemorrhage) in pre-clampsia
Evaluation of the efficacy of prophylactic oral and rectal misoprostol for reducing PPH (post-partum hemorrhage) in pre-clampsia
-
Design
-
A randomized clinical trial with 2 intercention and 1 control groups, with parellel groups, double blinded, phase 3 on 126 patients, pockent shuffling was used for randomization.
-
Settings and conduct
-
The main researcher patients and data analyzer are blind to the study groups. After randomization with the shuffled pocket method, the patient enters the group at random. After spinal anesthesia with the same protocol and C-section, immediately after the umbilical cord clamp, the first group was injected with 400 micrograms of rectal misoprostol, the second group with 400 micrograms of rectal misoprostol. All groups including the control group only recieve 30 U of Oxytocin according to the national protocol.
-
Participants/Inclusion and exclusion criteria
-
Inclusion:
Age between 18 to 45 years
Pregnant mothers with severe pre-eclampsia
Hospitalization for C-section
Gestational age over 35 weeks
A maximum of 2 previous cesarean sections
Complete removal of the placenta after cesarean section
Exclusion:
Chronic hypertension
Placental abnormality
Complications or emergent condition during surgery
High bleeding risk
Indication for hysterectomy or TL
-
Intervention groups
-
Oral misoprostol
Rectal misoprostol
Control
-
Main outcome variables
-
Gauzes count for blood loss volume will be performed after the operation, 1 hour, 4 hours after surgery, and hemoglobin and hematocrit will be measured 24 hours after delievery.
General information
-
Reason for update
-
Only 126 patients were changed to 128 patients.
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20201022049108N1
Registration date:
2020-11-05, 1399/08/15
Registration timing:
prospective
Last update:
2022-05-22, 1401/03/01
Update count:
1
-
Registration date
-
2020-11-05, 1399/08/15
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2020-11-21, 1399/09/01
-
Expected recruitment end date
-
2022-01-21, 1400/11/01
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Evaluation of the Efficacy of Rectal or Sub-linguinal Misoprostol concomitant with Oxytocin for Prevention of Postpartum Hemorrhage in women with preeclampsia
-
Public title
-
Evaluation of the effects of prophylactic misoprostol with oxytocin for postpartum hemorrhage in women with preeclampsia
-
Purpose
-
Prevention
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
ALL pregnant mothers with severe pre-eclampsia who referred to the Shahi Kamali educational center in the study period
Hospitalization for C-section
Gestational age over 35 weeks
Having a healthy and alive fetus
Cephalic fetus
A maximum of 2 previous cesarean sections
Complete removal of the placenta after cesarean section
The age of 18-45 years
Exclusion criteria:
Mothers with coagulation disorders
History of maternal blood disorders
Chronic hypertension
Placental adhesion such as placenta previa and ecrta
Placental abruption (overt and covert)
Complications or emergency during surgery
Eclampsia
Mild pre-eclampsia
Abnormal placenta
History of uterine rupture
High bleeding risk
Indication for hysterectomy or TL
-
Age
-
From 18 years old to 45 years old
-
Gender
-
Female
-
Phase
-
3
-
Groups that have been masked
-
- Participant
- Data analyser
-
Sample size
-
Target sample size:
128
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Pocket shuffling, In this study for a total sample size of 128, the principle investigator write number 1 on 43 blanck cards, number 2 on 43 blanck cards, number 3 on 43 blanck cards. Then, she place them in non-transparent pockets, then give all of them to another person that will shuffle them and put them in a box and give the box back to PI. For every patients included in the study, the PI picks up one card and assign the patient to one of the 3 groups based on the information on that card.
The rest of the cards is then shuffled again and placed in a box to be used by another patient. This continues until the last patient.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
First, dark envelopes were prepared for the number of total sample size, the inside of which was not visible in the light, and a paper that the name of groups was written on them were placed in them and placed in the operating room. The surgeon picks up an envelope and gives it to the PI. Based on the information in the envelope, the PI prescribes the medication for the patient. The patients and data analyzer will not know what kind of tratment were prescribed.
-
Placebo
-
Not used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2020-10-10, 1399/07/19
-
Ethics committee reference number
-
IR.ABZUMS.REC.1399.186
Health conditions studied
1
-
Description of health condition studied
-
severe pre-eclampsia
-
ICD-10 code
-
O14.13
-
ICD-10 code description
-
Severe pre-eclampsia, third trimester
Primary outcomes
1
-
Description
-
Bleeding volume with gauze counting
-
Timepoint
-
Immediately, 1 hour, and 4 hours after C-section
-
Method of measurement
-
gauze counting
2
-
Description
-
Hemoglobin and hematocrit changes
-
Timepoint
-
24 hours after C-section
-
Method of measurement
-
Blood test
Intervention groups
1
-
Description
-
Intervention group: Oral misoprostol manufactured in Aboorehyan pharmacy CO, Iran, give to patients sublingually after C-section it is in combination with conventional treatment that is infusion of 30 IU (3 X ampule 10 IU/mL) of same company.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: Without Intervention: after C-section aconventional treatment that is infusion of 30 IU (3 X ampule 10 IU/mL) of Abooreyhan pharmacy CO. Iran. will give to patients.
-
Category
-
N/A
3
-
Description
-
Intervention group: rectal misoprostol, Oral misoprostol manufactured in Aboorehyan pharmacy CO, iran, give to patients rectally after C-section it is in combination with conventional treatment that is infusion of 30 IU (3 X ampule 10 IU/mL) of same company.
-
Category
-
Treatment - Drugs
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Karaj University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
No - There is not a plan to make this available
-
Statistical Analysis Plan
-
No - There is not a plan to make this available
-
Informed Consent Form
-
No - There is not a plan to make this available
-
Clinical Study Report
-
Yes - There is a plan to make this available
-
Analytic Code
-
No - There is not a plan to make this available
-
Data Dictionary
-
Not applicable
-
Title and more details about the data/document
-
Results of the study will be published. The study protocol and statistical analysis will be included in the manuscript
-
When the data will become available and for how long
-
One year after finishing the study, data will be published and will be available in databases
-
To whom data/document is available
-
After permission form the sponsor, data of the study will be available for academic researchers, physicians and scientific institutes
-
Under which criteria data/document could be used
-
Other researchers are permitted to included the results in their systematic reviews and metaanalysis
-
From where data/document is obtainable
-
Mina Ataee, Shahid Kamali Hospital, Alborz
-
What processes are involved for a request to access data/document
-
After receiving the query, dependent on the requested data, the scientific responsible person of the study will response to the query in coordinate with the sponsor within 2 weeks
-
Comments
-